Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 7 - The Untold Story

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead

Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments

MarketBeat

Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs

Eli Lilly and Co (NYSE:LLY) on Wednesday shared topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials of oral orforglipron for reducing blood sugar levels.

Benzinga

Don’t give in to big pharma on drug pricing

Letter: Drug manufacturers may lament the UK’s drug prices, writes Simon Dixon, but the NHS should celebrate them

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Healthcare Companies Insiders Are Buying

Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years.

MarketBeat

Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs

As the largest publicly traded U.S. healthcare enterprise, Eli Lilly Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powerful in 2023 and 2024, which saw LLY stock rise from around $360 to approximately $960 in late summer of last year. However,…

Benzinga

TikTok influencers fuelling parallel market for unlicensed weight-loss drug

Guardian finds a thriving trade on Telegram for retatrutide, which is still in clinical trials and illegal to sell

The Guardian - UK

Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations

Bill Gates and the Pan American Health Organization (PAHO) are reportedly developing plans to expand access to popular weight-loss drugs such as Novo Nordisk A/S’ (NYSE:NVO) Wegovy and Eli Lilly and Co.’s (NYSE:LLY) Mounjaro in low- and middle-income countries.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

5 Healthcare Plays Powering the Sector’s Big Comeback

After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.

MarketBeat

Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Long-Term Study Shows Sustained Remission With Eli Lilly's Ulcerative Colitis Drug

Eli Lilly and Co. (NYSE:LLY) unveiled new data on Tuesday from LUCENT-3, the single-arm long-term Phase 3 open-label extension of LUCENT-1 and LUCENT-2, which evaluated the efficacy and safety of mirikizumab in patients with ulcerative colitis for an additional three years of treatment (up to four years total).

Benzinga

Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal

Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.

MarketBeat

Eli Lilly Eyes India For Manufacturing, Plans To Spend $1 Billion

Eli Lilly and Co. (NASDAQ:LLY) plans to invest over $1 billion in India to strengthen its manufacturing network, according to Reuters.

Benzinga

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

MarketBeat

Eli Lilly Shares Are Trading Higher Wednesday: What's Going On?

Eli Lilly And Company (NYSE:LLY) shares are trading higher Wednesday after President Donald Trump recently announced a deal with Pfizer as well as the ‘TrumpRx’ site to decrease prices.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away

Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend "most favored nation" (MFN) pricing to Medicaid, Pfizer bought itself a…

Barchart

Stocks Settle Higher as Drug Makers and Chip Stocks Rally

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.28%. December E-mini S&P futures (ESZ25 ) rose +0.39%, and December E-mini Nasdaq futures...

Euronews

Big Pharma’s retreat: Is NHS pricing behind investor pullbacks?

Multinational pharmaceutical firms are pulling pack or pausing investments in the UK, blaming a lack of competitive drug pricing.

Barchart

Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?

As the battle for dominance heats up in the weight loss market, which stock is a better investment now?

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

The Conversation

What is lecanemab, the newly approved Alzheimer’s drug? Can it really slow down dementia?

Dementia is a condition that results in progressive memory or thinking problems. It’s now the most common cause of death in Australia. There are many different causes of dementia, but Alzheimer’s disease accounts for around 60–80% of all cases.

The Independent UK

NHS facing ‘critical threat’ after Trump pressure to hike drug prices

NEWS ANALYSIS: Drug prices in the UK could rise amid 100 per cent tariffs on branded medicines and pressure from US President Donald Trump to stop ‘global freeloading’, Alicja Hagopian reports

Benzinga

FDA Approves Eli Lilly's Drug For Advanced Breast Cancer

On Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE: LLY) Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET).

Benzinga

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move?

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The termination is a setback for Lilly’s obesity pipeline among growing investor expectations.

Benzinga

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch

On Wednesday, Eli Lilly Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

The Guardian - UK

Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility

‘We’re here to invest,’ says Darius Hughes as he calls comments by other pharma companies ‘a little harsh’

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.